China Pharma Holdings, Inc. — Q2 2020 Form 10-Q
Reporting period: Three and six months ended June 30, 2020. Unaudited consolidated results; the company develops, manufactures, and markets pharmaceuticals in China.
Key financial results
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $3.77 million | $2.57 million | $5.53 million | $5.50 million |
| Gross profit / margin | $1.15 million / 30.5% | $0.16 million / 6.4% | $1.34 million / 24.3% | $0.82 million / 14.9% |
| Operating income (loss) | $0.07 million | ($0.75 million) | ($0.52 million) | ($1.09 million) |
| Net income (loss) | $0.01 million | ($0.84 million) | ($0.65 million) | ($1.26 million) |
| Operating cash flow | Not presented quarterly | Not presented quarterly | ($0.15 million) | $0.15 million |
- Q2 basic and diluted EPS was $0.00, versus a loss of $0.02; six-month EPS was a loss of $0.01, versus a loss of $0.03. Weighted-average shares were 43,579,557.
- Six-month selling expenses were $1.05 million, general and administrative expenses $0.71 million, research and development $0.08 million, and interest expense $0.13 million.
- At June 30, cash and cash equivalents were $1.81 million and restricted cash $0.22 million. Current assets were $7.26 million versus current liabilities of $11.34 million. Total assets were $23.17 million; total liabilities $14.77 million; stockholders’ equity $8.40 million.
- Debt included $4.10 million outstanding on the construction loan and $1.91 million on lines of credit. The filing lists $3.32 million of principal due in the twelve months ending June 30, 2021. The company made a scheduled construction-loan principal payment of approximately $2 million on July 10, 2020.
- Six-month investing cash outflow was $0.84 million, primarily for mask production lines; financing cash inflow was $1.87 million, largely from new bank credit lines. Cash, cash equivalents, and restricted cash increased by $0.85 million.
Material changes and drivers
- Q2 revenue rose 46.8%, but the increase was attributable to a one-time $1.70 million export trade of COVID-19 diagnostic test kits purchased from a third party. Excluding that trade, Q2 pharmaceutical revenue was about $2.07 million, down from $2.57 million.
- For the first half, reported revenue was nearly flat year over year, while domestic pharmaceutical revenue fell to $3.83 million from $5.50 million; the COVID-19 test-kit trade contributed $1.70 million. Excluding that trade, pharmaceutical revenue declined about 31%.
- Gross margin improved in both periods, which management attributed mainly to the test-kit transaction. The company remained loss-making for the six-month period.
- Six-month cost of revenue fell to $4.19 million from $4.68 million. Selling expenses increased to $1.05 million from $0.98 million; G&A and R&D expenses declined.
Outlook, risks, and unusual items
- Going concern: The company reported an accumulated deficit of $26.6 million and stated that substantial doubt exists about its ability to continue as a going concern within one year after issuance. Management cited expected operating losses, debt service, and working-capital needs. It is pursuing advance-payment sales, stronger receivables collection, strategic alternatives including nutrition products, and potential borrowing against fixed assets; management said these plans were not finalized and could not be considered probable of implementation.
- Management warned that operating cash and newly obtained credit may not be sufficient for the next twelve months and that additional financing may not be available on acceptable terms. All reported cash and cash equivalents were held in the Chinese subsidiary and considered indefinitely reinvested, not expected to be available to the parent or shareholders.
- New credit facilities included a Postal Savings Bank line of up to RMB 10 million, with RMB 5 million advanced by June 30 and additional advances in July, and a Bank of Communications line of RMB 8.5 million, fully advanced on June 30. Both were personally guaranteed by the CEO; the latter also involved pledged personal assets. The construction loan had a scheduled substantial payment shortly after quarter-end.
- COVID-19 caused operational and distribution disruption; the filing cautions that renewed outbreaks, supplier or customer disruption, and broader economic effects could harm results. The test-kit trade was described as one-time, not recurring guidance.
- Revenue is concentrated: one customer represented 30.7% of first-half sales; two customers represented 49.8% and 10.7% of receivables. Two suppliers accounted for 39.0% and 18.6% of raw-material purchases. Three products accounted for 65.9% of revenue.
- Receivables were heavily aged: 96.3% of the reported aging distribution was over 720 days, and the allowance for doubtful accounts was $17.34 million against net trade receivables of $0.60 million. This remains a material collection and estimation risk.
- PRC drug-price controls and expanded group purchasing pressure pharmaceutical pricing. Generic-drug consistency evaluation policies remain dynamic, and the company reported slower progress and extended approval timelines for pipeline formulas. RMB conversion and remittance are subject to government controls.
- Disclosure controls were deemed ineffective at June 30, 2020 due to a material weakness involving insufficient accounting and financial-reporting personnel knowledgeable in U.S. GAAP. Management nevertheless stated the interim financial statements were fairly stated in all material respects.
Important facts for investors to verify
- Whether the company can fund operations and meet debt maturities without additional financing, and whether management’s going-concern plans become executable.
- Whether the $1.70 million COVID-19 test-kit transaction is repeatable; assess underlying pharmaceutical sales and margins without it.
- Actual collection performance on the severely aged receivables, adequacy of the allowance, and exposure to concentrated customers.
- Post-quarter debt advances and repayments, remaining availability under credit facilities, and guarantees or collateral securing them.
- Progress in remediating the material weakness and improving disclosure controls, as well as any changes in drug pricing, approval requirements, or foreign-exchange restrictions.